Two Sigma Advisers LP Buys Shares of 64,400 The Clorox Company (NYSE:CLX)

Two Sigma Advisers LP acquired a new position in shares of The Clorox Company (NYSE:CLX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 64,400 shares of the company's stock, valued at approximately $10,459,000. Two Sigma Advisers LP owned about 0.05% of Clorox at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in CLX. Merit Financial Group LLC lifted its stake in Clorox by 17.3% during the fourth quarter. Merit Financial Group LLC now owns 2,274 shares of the company's stock worth $369,000 after purchasing an additional 336 shares during the last quarter. Ballentine Partners LLC lifted its stake in Clorox by 5.4% during the fourth quarter. Ballentine Partners LLC now owns 2,608 shares of the company's stock worth $424,000 after purchasing an additional 134 shares during the last quarter. SG Americas Securities LLC lifted its stake in Clorox by 489.2% during the fourth quarter. SG Americas Securities LLC now owns 115,252 shares of the company's stock worth $18,718,000 after purchasing an additional 95,691 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in Clorox by 7.9% during the fourth quarter. Janney Montgomery Scott LLC now owns 109,275 shares of the company's stock worth $17,747,000 after purchasing an additional 7,983 shares during the last quarter. Finally, Independent Wealth Network Inc. lifted its stake in Clorox by 7.2% during the fourth quarter. Independent Wealth Network Inc. now owns 4,264 shares of the company's stock worth $692,000 after purchasing an additional 287 shares during the last quarter. 78.53% of the stock is currently owned by institutional investors.

Clorox Trading Up 0.4%

CLX traded up $0.53 during trading on Wednesday, reaching $130.89. The company had a trading volume of 319,621 shares, compared to its average volume of 1,333,471. The firm's 50-day simple moving average is $139.05 and its 200 day simple moving average is $151.85. The company has a market cap of $16.13 billion, a price-to-earnings ratio of 35.78, a PEG ratio of 2.62 and a beta of 0.60. The Clorox Company has a 12-month low of $127.60 and a 12-month high of $171.37. The company has a debt-to-equity ratio of 20.52, a quick ratio of 0.60 and a current ratio of 0.94.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The company had revenue of $1.67 billion during the quarter, compared to analysts' expectations of $1.74 billion. During the same period in the prior year, the business posted $1.71 EPS. The company's revenue for the quarter was down 8.0% compared to the same quarter last year. Equities research analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current year.

Insider Buying and Selling at Clorox

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction on Wednesday, May 7th. The shares were bought at an average price of $136.57 per share, with a total value of $546,280.00. Following the purchase, the director now directly owns 4,000 shares in the company, valued at $546,280. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.57% of the company's stock.

Wall Street Analyst Weigh In

CLX has been the topic of a number of recent research reports. Wells Fargo & Company cut their target price on Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. JPMorgan Chase & Co. cut their target price on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. UBS Group cut their target price on Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Citigroup cut their target price on Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a research note on Monday, April 14th. Finally, Morgan Stanley cut their target price on Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $151.23.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.